Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pristiq desvenlafaxine: Phase III data

In a double-blind, 8-week, U.S. Phase III trial in 447 patients, 50 mg/day

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE